2021
DOI: 10.1007/s11302-021-09774-x
|View full text |Cite
|
Sign up to set email alerts
|

Targeting P2 receptors in purinergic signaling: a new strategy of active ingredients in traditional Chinese herbals for diseases treatment

Abstract: Adenosine triphosphate (ATP) and its metabolites adenosine diphosphate, adenosine monophosphate, and adenosine in purinergic signaling pathway play important roles in many diseases. Activation of P2 receptors (P2R) channels and subsequent membrane depolarization can induce accumulation of extracellular ATP, and furtherly cause kinds of diseases, such as pain-and immune-related diseases, cardiac dysfunction, and tumorigenesis. Active ingredients of traditional Chinese herbals which exhibit superior pharmacologi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 171 publications
0
1
0
Order By: Relevance
“…In the purinergic system, growing evidence supported that purinergic P2X7Rs play important role in different cancers, including lung cancer, colorectal cancer, breast cancer, and acute myeloid leukemia [12][13][14][15][16][17][18][19]. Apart from the strategy targeting the P2X7 ion channel, from antibodies and nanobodies to small-molecule drugs, which has been proved to improve the outcomes in models of cancer [20][21][22][23][24], the nature product is also taken into account for the development of potential anti-cancer drug to target purinergic receptors [25,26]. Atractylenolide I (Atr-I, Fig.…”
Section: Introductionmentioning
confidence: 99%
“…In the purinergic system, growing evidence supported that purinergic P2X7Rs play important role in different cancers, including lung cancer, colorectal cancer, breast cancer, and acute myeloid leukemia [12][13][14][15][16][17][18][19]. Apart from the strategy targeting the P2X7 ion channel, from antibodies and nanobodies to small-molecule drugs, which has been proved to improve the outcomes in models of cancer [20][21][22][23][24], the nature product is also taken into account for the development of potential anti-cancer drug to target purinergic receptors [25,26]. Atractylenolide I (Atr-I, Fig.…”
Section: Introductionmentioning
confidence: 99%